Please use this identifier to cite or link to this item: https://biore.bio.bg.ac.rs/handle/123456789/6911
Title: Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine
Authors: Salehi, Bahare
Selamoglu, Zeliha
Mileski, Ksenija 
Pezzani, Raffaele
Redaelli, Marco
Cho, William C
Kobarfard, Farzad
Rajabi, Sadegh
Martorell, Miquel
Kumar, Pradeep
Martins, Natália
Subhra Santra, Tuhin
Sharifi-Rad, Javad
Keywords: DepoCyt;cancer therapy;chemotherapy;liposomal ara-C;liposomal cytarabine;liposomal cytosine arabinoside
Issue Date: 23-Nov-2019
Journal: Biomolecules
Volume: 9
Issue: 12
Start page: 773
Abstract: 
Cancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients. In the last decades, chemotherapy has been well developed. Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells.. In this context, the possibility to use an encapsulated anti-cancer drug may potentially solve the problem. Liposomal cytarabine is a formulation with pronounced effectiveness in lymphomatous meningitis and reduced cardiotoxicity if compared to liposomal anthracyclines. Thus, the future liposomal cytarabine use could be extended to other diseases given its reduction in cytotoxic side effects compared to the free formulation. This review summarizes the chemistry and biology of liposomal cytarabine, with exploration of its clinical implications.
URI: https://biore.bio.bg.ac.rs/handle/123456789/6911
ISSN: 2218-273X
DOI: 10.3390/biom9120773
Appears in Collections:Journal Article

Show full item record

SCOPUSTM   
Citations

52
checked on Nov 17, 2024

Page view(s)

10
checked on Nov 20, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.